‌

US Patent 11033633 ExPEC glycoconjugate vaccine formulations

Patent 11033633 was granted and assigned to Janssen Pharmaceuticals on June, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Janssen Pharmaceuticals

0

Current Assignee

Janssen Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Wouter Frank Tonnis0

Janik Adriaansen0

Olga Labovitiadi0

Francesco Doro0

Date of Patent

June 15, 2021

0

Patent Application Number

167092230

Date Filed

December 10, 2019

0

Patent Citations

US Patent 10159751 ExPEC glycoconjugate vaccine formulations

Patent Citations Received

US Patent 12076385 Methods and compositions for immune protection against extra-intestinal pathogenic

0

US Patent 11529405 MDR

US Patent 11446370 Bioconjugates of

US Patent 11931405 Bioconjugates of

0

US Patent 11491220 Methods of producing bioconjugates of

Patent Primary Examiner

0

Patent abstract

Compositions and methods for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) are described. In particular, multivalent vaccines containing O-antigen polysaccharide covalently bound to an exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein that can withstand multiple environmental stresses are described.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11033633 ExPEC glycoconjugate vaccine formulations

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.